My mother died in my home in hospice in 2020, on the day my state of Washington went into COVID-19 lockdown. Her body was ...

cCFF Therapeutics Development Center, National Jewish Health, Denver, CO, USA dDepartments of Internal Medicine and Pediatrics, Divisions of Pulmonary ... effects in a small number of people with ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

Engineers Design Lookalike Drug Carrier to Evade Lung's Lines of Defense Aug. 22, 2024 — Managing hard-to-treat respiratory illnesses like asthma and pulmonary fibrosis just got easier if a new ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...